Oppenheimer Asset Management Inc. Genmab A/S Transaction History

Oppenheimer Asset Management Inc.

$8.04 Billion
Q3 2024

A detailed history of Oppenheimer Asset Management Inc. transactions in Genmab A/S stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 232,243 shares of GMAB stock, worth $4.78 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

232,243

Previous 218,078 6.5%

Holding current value

$4.78 Million

Previous $5.48 Million 3.32%

% of portfolio

0.07%

Previous 0.07%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$23.84 - $28.48 $337,693 - $403,419	14,165 Added 6.5%	232,243 $5.66 Million
Q2 2024 Aug 08, 2024	BUY	$25.13 - $30.27 $1.14 Million - $1.37 Million	45,376 Added 26.27%	218,078 $5.48 Million
Q1 2024 May 06, 2024	SELL	$26.43 - $32.77 $289,434 - $358,864	-10,951 Reduced 5.96%	172,702 $5.17 Million
Q4 2023 Feb 13, 2024	SELL	$27.94 - $35.44 $271,241 - $344,051	-9,708 Reduced 5.02%	183,653 $5.85 Million
Q3 2023 Nov 07, 2023	BUY	$35.27 - $42.24 $111,135 - $133,098	3,151 Added 1.66%	193,361 $6.82 Million
Q2 2023 Aug 02, 2023	BUY	$37.4 - $42.94 $2.98 Million - $3.43 Million	79,783 Added 72.25%	190,210 $7.23 Million
Q1 2023 May 10, 2023	BUY	$34.88 - $43.22 $15,870 - $19,665	455 Added 0.41%	110,427 $4.17 Million
Q4 2022 Feb 06, 2023	SELL	$33.8 - $47.06 $870,451 - $1.21 Million	-25,753 Reduced 18.97%	109,972 $4.66 Million
Q3 2022 Nov 14, 2022	SELL	$31.52 - $373.61 $137,395 - $1.63 Million	-4,359 Reduced 3.11%	135,725 $4.36 Million
Q2 2022 Aug 08, 2022	BUY	$26.83 - $38.57 $86,607 - $124,503	3,228 Added 2.36%	140,084 $4.55 Million
Q1 2022 May 12, 2022	SELL	$30.95 - $39.68 $783,035 - $1 Million	-25,300 Reduced 15.6%	136,856 $4.95 Million
Q4 2021 Feb 02, 2022	SELL	$35.87 - $47.12 $239,719 - $314,902	-6,683 Reduced 3.96%	162,156 $6.42 Million
Q3 2021 Nov 12, 2021	SELL	$41.55 - $48.72 $629,150 - $737,718	-15,142 Reduced 8.23%	168,839 $7.38 Million
Q2 2021 Aug 03, 2021	BUY	$32.88 - $44.57 $230,160 - $311,990	7,000 Added 3.96%	183,981 $7.51 Million
Q1 2021 May 17, 2021	BUY	$30.92 - $44.4 $398,960 - $572,893	12,903 Added 7.86%	176,981 $5.81 Million
Q4 2020 Feb 11, 2021	BUY	$33.66 - $40.76 $177,859 - $215,375	5,284 Added 3.33%	164,078 $6.67 Million
Q3 2020 Nov 13, 2020	SELL	$33.07 - $38.68 $1.01 Million - $1.19 Million	-30,653 Reduced 16.18%	158,794 $5.81 Million
Q2 2020 Aug 11, 2020	SELL	$20.05 - $33.89 $1.11 Million - $1.87 Million	-55,225 Reduced 22.57%	189,447 $6.42 Million
Q1 2020 May 08, 2020	BUY	$17.15 - $25.22 $141,161 - $207,585	8,231 Added 3.48%	244,672 $5.18 Million
Q4 2019 Feb 07, 2020	BUY	$18.88 - $24.14 $2,605 - $3,331	138 Added 0.06%	236,441 $5.28 Million
Q3 2019 Oct 31, 2019	BUY	$18.0 - $21.38 $4.25 Million - $5.05 Million	236,303 New	236,303 $4.79 Million

Others Institutions Holding GMAB

# of Institutions

236

Shares Held

52.5M

Call Options Held

10.2K

Put Options Held

25.5K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.

Account

Oppenheimer Asset Management Inc. Genmab A/S Transaction History